← Back to Search

Monoclonal Antibodies

STRO-001 for Non-Hodgkin's Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Sutro Biopharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial is testing a new drug to see if it is safe and effective. The drug will be given intravenously every 3 weeks.

Eligible Conditions

Non-Hodgkin's Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
B-Cell Tumors
Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Part 1: Define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of STRO-001

Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001)

Part 2: Evaluate preliminary anti-tumor activity (NHL patients)

+1 more

Secondary outcome measures

Part 1: Assess the immunogenic potential of STRO-001

Part 1: Characterize the PK of STRO-001 by measuring the clearance (CL)

Pyruvate Kinase

+10 more

Other outcome measures

Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (NHL)

Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (multiple myeloma patients)

Trial Design

1Treatment groups

Experimental Treatment

Group I: STRO-001Experimental Treatment1 Intervention

intravenous

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sutro Biopharma, Inc.Lead Sponsor

4 Previous Clinical Trials

950 Total Patients Enrolled

Arturo Molina, MDStudy DirectorSutro Biopharma

2 Previous Clinical Trials

218 Total Patients Enrolled

Media Library

STRO-001 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03424603 — Phase 1

Non-Hodgkin's Lymphoma Research Study Groups: STRO-001

Non-Hodgkin's Lymphoma Clinical Trial 2023: STRO-001 Highlights & Side Effects. Trial Name: NCT03424603 — Phase 1

STRO-001 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03424603 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has STRO-001 attained regulatory clearance from the FDA?

"As this is a Phase 1 trial, with only limited data on its efficacy and safety, STRO-001 has been given the lowest risk score of 1."

Answered by AI

To what extent is this clinical trial being implemented at medical institutions?

"Weill Cornell Medicine, UT Southwestern Medical Center and Emory University Winship Cancer Institute are the 3 primary sites conducting this research. Additionally, 12 other locations have been incorporated into the study's scope."

Answered by AI

What are the primary objectives of this research endeavor?

"The primary goal of the 18-month medical study is to evaluate preliminary anti-tumor activity for multiple myeloma patients. The secondary outcomes involve measuring maximum plasma concentration, ascertaining incidence of treatment adverse events and calculating terminal half life of STRO-001 after administration."

Answered by AI

How many individuals are being recruited for this research endeavor?

"Indeed, based on the information from clinicaltrials.gov this trial is presently recruiting participants. It was first announced to public on February 22nd 2018 and lastly updated at August 1st 2022. The study requires 220 people for enrollment spread across 12 different medical facilities."

Answered by AI

Are there any available slots for participants in this study?

"Yes, according to the information listed on clinicaltrials.gov this trial is currently recruiting participants. It was first announced on February 22nd 2018 and last updated August 1st 2022. The study plans to enroll 220 individuals across 12 medical centres."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

2018. "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03424603.